COX-2 in Colorectal Cancer {#s1}
==========================

Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer-related death in the world, with around 900,000 deaths per year ([@B38]; [@B66]). Even in patients who have undergone tumor resection, 40--50% relapse and die of metastases, being the overall 5-year survival less than 60%. Despite this health burden, only few therapeutic options exist for this disease, including combination of chemotherapy and anti-angiogenic agents ([@B70]; [@B64]). Thus, currently available therapeutic options do not achieve the desired efficiency and development of new strategies is required.

There are two types of CRC: hereditary or familial colon cancer and sporadic colon cancer ([@B108]; [@B79]). Nonetheless, sporadic colon cancer is the most common with an incidence of 75--80% in diagnosed cases. The alterations generated in two main molecular pathways subdivide this type of cancer. In 80--85% of sporadic CRCs there are mutations or deletions in suppressor genes such as KRAS, APC, DCC, and p53, promoting chromosomal instability ([@B108]; [@B81]). In 1990, Fearon and Vogelstein proposed that the mutation in three or four of the aforementioned oncogenes and/or suppressor genes is necessary to initiate the tumorigenesis process, where the final properties of the tumor are determined from the accumulation and order in which changes appear ([@B33]). Later, it was described how the epithelial cells of the CRC acquire the genetic alterations in a strict order and involve the Wnt and TGFβ signaling pathways in cancer promotion ([@B3]). On the other hand, the non-canonical route, also called "mutator", comprises 15--20% of sporadic CRCs and depends mainly on the alteration due to the instability of microsatellite sequences (MSI, Microsatellite Sequences Instability) in the genome due to the accumulation of mutations in the genes for rupture repair (MMR, Mismatch Repair) produced during DNA replication ([@B52]).

Many clinical trials and epidemiological studies have suggested that the use of non-steroidal anti-inflammatory drugs (NSAIDs), which are classic inhibitors of COX enzymatic activity reduce the risk of developing cancer in general, and more specifically in CRC (reviewed in ([@B128]; [@B106]; [@B96]; [@B93]). Taking together all these data strongly suggest that Cox targeting is a mechanism for cancer prevention.

COX enzymes catalyse the rate limiting step in the conversion of arachidonic acid, derived from membrane phospholipids by phospholipase A2, into prostanoids ([@B140]). Two main isoforms of this enzyme are known: COX-1 encoded by prostaglandin-endoperoxide synthase 1 (*PTGS1*) and COX-2 (encoded by *PTGS2*). Although both proteins show the same cyclooxygenase and peroxidase activity, their differences are found in substrates, cell expression, inhibition, and intracellular localization and induction ([@B36]). COX-1 is constitutively expressed in most tissues and involved in physiological processes. However, COX-2 is not usually detectable in normal tissues but is induced by numerous cytokines, growth factors, hormones, and tumor promoters. Prostanoids modulate immune responses, renal function, blood clotting and play a role in many pathological conditions, such as inflammation, pain, fever, swelling, etc. ([@B53]; [@B54]; [@B119]).

Considerable amounts of evidence in clinical settings further support a role of COX-2 in colorectal carcinogenesis and tumor progression \[reviewed in ([@B123]; [@B133])\]. Thus, COX-2 is expressed early during the adenoma-carcinoma sequence that occurs in CRC, suggesting an important role of this enzyme in colorectal carcinogenesis. COX-2 expression is upregulated in human colorectal adenocarcinomas when compared with normal adjacent colonic tissue. Moreover, polymorphisms of the *PTGS2* gene were associated with risk of CRC ([@B24]; [@B1]). The use of Min/+ mice as a CRC model showed elevated levels of COX-1 and COX-2 in sporadically formed adenomas ([@B141]) and inhibition of COX-2 resulted in a substantial decrease in intestinal polyp number and size ([@B55]). In the same way, Apc716 mice developed a smaller number and size of tumor polyps when the COX-2 gene was eliminated ([@B89]).

In addition, many reports of colorectal tumor cells either overexpressing COX-2 or having it silenced have correlated increased COX-2 expression with their invasive and metastatic properties in xenografted tumors in mice ([@B130]; [@B131]; [@B87]; [@B19]; [@B124]; [@B147]; [@B17]; [@B122]; [@B120]). However, the molecular mechanisms by which COX-2 expression in intestinal epithelial cells leads to that phenotype have not been fully elucidated yet.

In view of the abundant biological and phenotypic evidence, several clinical trials have been performed, aimed to evaluate the efficacy of specific inhibitors of COX-2 (COXIBs) ([@B34]) to prevent or delay the onset (or recurrence) of tumors in high-risk patients, including those with prior removal of colon tumors. These studies indicate that specific inhibition of COX-2 prevents the (re)appearance of tumors but also show cardiovascular side-effects \[reviewed in ([@B116]; [@B7])\].

Recent studies, remark the role of COX-2 in constitutive IDO1 expression by human tumors and substantiate the use of COX-2 inhibitors to improve the efficacy of cancer immunotherapy, either by reducing constitutive IDO1 expression, which contributed to the lack of T-cell infiltration in tumors that fail to respond to immunotherapy ([@B46]), or by synergizing with anti-checkpoint antibodies ([@B149]).

For all of the above, the study of the expression of COX-2 in the different phases of tumor progression and metastasis and the finding of new signaling pathways triggered by this enzyme are essential in order to develop new drugs that inhibit the effects of COX-2 both in cancer prevention and therapy ([@B104]).

Prostanoids in Colon Cancer {#s2}
===========================

The activity of cyclooxygenases (COX) is coupled to several terminal synthases that produce the five primary different prostanoids: prostaglandin D2 (PGD~2~), prostaglandin E2 (PGE~2~), prostaglandin F2α (PGF~2α~), prostaglandin I2/prostacyclin (PGI~2~), and thromboxane A2 (TXA~2~) ([@B53]; [@B54]) being also some of them implicated in colon cancer.

PGE~2~ in Colon Cancer {#s2_1}
----------------------

Among the prostanoids, PGE~2~ has been proposed as the principal prostanoid promoting tumor growth and survival in CRC. PGE~2~ is present in the healthy colon but its levels are elevated in CRC ([@B98]; [@B14]; [@B154]) and correlate with tumor size ([@B98]; [@B146]) and disease progression ([@B64]). The elevation of PGE~2~ levels may favor tumor growth and invasion *via* several mechanisms as stimulating cell proliferation, inducing local immunosuppression, inhibiting apoptosis, promoting angiogenesis, and increasing cell migration and invasion as well as drug resistance in colon cancer cells ([@B53]; [@B23]; [@B39]; [@B133]; [@B64]). Moreover, there is a positive feedback loop between COX-2 and PGE~2~, in which COX-2 induces PGE~2~ production, and that in turn increases further the expression of COX-2 in colon cancer cells ([@B120]; [@B64]).

Three PGE~2~ synthases from PGH~2~ have been described ([@B45]), two microsomal, mPGES1, mPGES-2, and the cytoplasmic cPGES, encoded by the PTGES, PTGES2, and PTGES3 genes, respectively. MPGES1 expression has been associated to CRC incidence and prognosis ([@B111]; [@B109]) and has been proposed to cooperate with COX-2 to enhance tumor growth ([@B61]). cPGES is a non-inducible isoform, constitutively expressed in most tissues and associated with COX-1 activity while maintaining the production of PGE~2~ ([@B127]).

Notably, we found co-localization of COX-2 and MPGES1 in human CRC biopsies and that PTGS2 and PTGES gene expression levels strongly correlate in human microarray databases. Interestingly, we have described the joint induction of mPGES-1 and COX-2 by PGE~2~ due to the involvement of the transcription factor EGR1 (Early Growth Response Protein 1), representing a positive feedback loop between COX-2, mPGES-1, and PGE~2~ ([@B120]). Moreover, mPGES-1 overexpressing carcinoma cell lines have increased tumorigenic capacity *in vivo* indicating that high levels of any of the two enzymes is sufficient to enhance CRC growth ([@B120]). Our results demonstrate that mPGES1 is induced by COX-2 overexpression, *via* autocrine PGs release, likely PGF~2α~ through an EGR1-dependent mechanism in colon carcinoma.

Thus, mPGES1 has gained attention recently as alternative target to COX-2 for CRC chemoprevention and chemotherapy ([@B110]). In this sense, mPGES1 inhibitors have demonstrated promising effects in inhibiting colon carcinoma growth ([@B27]; [@B137]; [@B64]), that may circumvent the *in vivo* cardiovascular toxicity associated with COX-2 inhibitors.

PGE~2~ acts through its binding to prostanoid-E (EP) receptors. Four subtypes of EP receptors (EP1, EP2, EP3, EP4) have been identified. Their tissue-specific expression and activation trigger different signaling pathways that favor, for example, the cellular proliferation of the intestinal epithelium ([@B126]). EPs belong to the family of G-protein coupled receptors (GPCRs) and transduce PGE~2~ signaling through different intracellular messengers. EP2 and EP4 preferably increase intracellular levels of cyclic adenosine monophosphate (cAMP) while signaling by EP3 mostly mobilizes cAMP and the activation of EP1 mobilizes calcium (Ca^2+^) ([@B102]; [@B2]). In different mice models of colon cancer, genetic deletion of the EP1 ([@B65]), EP2 ([@B78]), and EP4 receptors inhibits colonic tumorigenesis ([@B82]).

Prostaglandin 2α in Colorectal Cancer {#s2_2}
-------------------------------------

PGF~2α~ is mainly produced by the activity of PGF synthase (PGFS) from PGH~2~ and specifically activates the GPCR type FP receptor ([@B10]; [@B69]). Signaling through the two FP isoforms leads to the activation of phospholipase C (PLC) and, consequently, an increase in intracellular Ca^2+^ and the activation of protein kinase C (PKC). However, PGF~2α~ can be synthesized from other PGs such as PGE~2~ and PGD~2~, and can signal through other receptors such as EP1 and EP3, thus varying the intracellular signaling pathways ([@B10]; [@B69]). For example, induction of COX-2 through FP can occur through Rho activation and transcription mediated by β-catenin/Tcf ([@B35]). Along those lines, elevated levels of cAMP have been detected in cells isolated from colonic crypts after treatment with PGF~2α~ ([@B22]).

There is very little evidence of the possible role of PGF~2α~ in CRC other than its higher levels, together with PGE~2~ ([@B86]). Also, in the tumor tissue of patients with CRC, a differential regulation of the cancer-dependent FP receptor has been detected ([@B42]). PGF~2α~ also promotes the invasion and mobility of epithelial cells of adenomas and colon carcinomas in collaboration with PGE~2~ ([@B100]).

Recently, we have shown that colorectal tumor cells produce PGF~2α~ though COX-2 and have provided some evidence that PGF~2α~ may also play a role in colorectal tumorigenesis ([@B120]). Colorectal adenoma and carcinoma-derived cell lines secrete PGF~2α~ while they also express FP indicating potential autocrine effects. Interestingly, this secreted PGF~2α~ was able to increase mPGES1 but also COX-2 in colon carcinoma cells, *via* FP receptor and EGR1, further enhancing PGE~2~ levels indicating a positive feedback loop between COX-2/mPGES1/PGE~2~ and PGF~2α~ ([@B120]). However, PGF~2α~ failed to directly induce cell proliferation in CRC cell lines ([@B12]).

Other Prostanoids {#s2_3}
-----------------

The roles of the other COX-derived prostanoids in CRC tumors, as well as in carcinoma cell lines remains poorly understood ([@B13]). It has been reported that the levels of some prostaglandin receptors, such as IP (PGI~2~ receptor) and DP (PGD~2~ receptor), were reduced in CRC cells and the downregulation of one of them, DP2, has been related to differentiation of healthy epithelium to tumor ([@B42]). The expression of thromboxane synthase (TXS), the enzyme that catalyses the conversion of PGH2 to TXA~2~, was significantly increased in CRC tumors compared to normal tissue. Furthermore, genetic or pharmacological reduction of TXS diminishes proliferation in CRC cell lines ([@B31]). In addition it has also been described that the lack of the enzyme 15-PGDH, responsible for the inactivation of prostaglandins and lipoxins, is associated with CRC ([@B4]) and together with the increase in the PGE~2~ synthesis, induces tumor formation in Min (multiple intestinal neoplasia) CRC model in mice. ([@B83]). Besides the loss of 15‐PGDH and induction of this enzyme has been associated with the suppression of inflammation-driven colon carcinogenesis in mice ([@B20]).

Prostaglandin Pathway and Colorectal Cancer {#s3}
===========================================

The potential implication of the Cox-PG synthases-PG receptors in CRC can be also studied through expression levels of the pathway´s components using The Cancer Genome Atlas (TCGA) gene expression data. A summary of these findings is shown in [**Figure 1**](#f1){ref-type="fig"}, based on the TCGA Colon Cancer dataset. These analyses, comparing tumor and normal colon epithelia, showed that gene expressions from several members of this pathway are upregulated in tumors, namely *PTGS2*, *PTGES*, and *TBXAS1*, indicating that the biosynthetic and signaling pathways of PGE~2~ and TXA~2~ are favored in established tumors. Conversely, expression downregulation in tumor tissue was observed for genes encoding components of the pathway leading to the signaling of other prostanoids, but most notably of *HPGD* that encodes the PGE~2~-inactivating enzyme 15-PGDH. Analysis with other different datasets, i.e., the OncoMine microarray database (Compendia Bioscience), resulted in very similar data regarding *PTGS2*, *PTGES* ([@B120]). Together, those analyses confirm the important role of COX2-2 and PGE~2~ in colon cancer. Nonetheless, since COX is the rate-limiting enzyme in the synthesis of all prostanoids, an increased expresion of this enzyme could result in the elevation of other prostanoids besides PGE~2~.

![Arachidonate-prostanoids pathway gene expression in colorectal cancer (CRC) tumors. Shown are mRNA expressions in tumors of enzymes and receptors from the arachidonate-prostanoids pathway. Numbers indicate the fold differences with normal adjacent tissue based on the The Cancer Genome Atlas (TCGA) Colon Cancer dataset.](fphar-11-00533-g001){#f1}

COX-2 Downstream Genes in CRC {#s4}
=============================

As mentioned above, the treatment of patients with NSAIDs or COXIBs greatly decreases tumor progression in a number of clinical trials in CRC. However, since general inhibitors of COXs, such as aspirin, can cause gastrointestinal bleeding problems and specific inhibitors of COX-2 increase the risk of cardiovascular disease, alternative treatments are needed targeting the downstream effector of COX-2 protumoral activity, likely minimizing side effects, and if possible aiming exclusively to cancer cells ([@B13]).

Although PGE~2~ blockade may represent a good therapeutic option, other PGs besides PGE~2~ could be responsible for COX-2 effect in colon carcinoma cells. Besides, although prostanoids may modulate the growth and invasiveness of colon carcinoma cells, they also modulate the immune responses and inflammation and their inhibition may also have unwanted side effects.

To address this issue, we have concentrated in the effects of COX-2 in colon carcinoma cells. COX-2 activity regulates gene expression, which confers cells advantages for growth, migration, invasion, and metastasis ([@B120]). We found that stable COX-2 overexpression in carcinoma cell lines (HT-29, HCT116, and Caco2) significantly affects gene transcription. Analysis of genes modified by COX-2 overexpression indicates that many genes involved in transcription, growth, apoptosis, angiogenesis, and migration were elevated (ArrayExpress, E-MEXP-2343). Moreover, a review of the available databases and literature in other carcinoma cell lines overexpressing COX-2 or repressed siRNA also identify some COX-2 downstream effectors responsible for the pro-tumorigenic properties of COX-2, although none of them performed a comprehensive gene expression analysis. Altogether, those analyses identified some interesting molecules. We selected some genes and validated them by quantitative RT-PCR in colon carcinoma cell lines, either induced by PGE~2~ or by overexpression of COX-2 or mPGES1. The results of mRNA levels obtained for some of those genes are shown in [**Table 1**](#T1){ref-type="table"}. Besides, we performed analyses of mRNA expression and survival in colon adenocarcinomas using public databases. From all these analyses some expected genes emerged, but others are relatively new and amenable to drug targeting.

###### 

Genes upregulated by COX-2, mPGES1, or PGE~2~.

              Cox-2^1^           PGE~2~^2^   mPGES^3^    COAD risk^4^   Metastasis risk^5^
  ----------- ------------------ ----------- ----------- -------------- --------------------
  *PTGS2*     Increased          Increased   Increased   No             Higher
  *PTGES*     Highly increased   NT          NT          Higher         Higher
  *DUSP4*     Increased          Increased   NT          NO             Higher
  *DUSP10*    Increased          Increased   Increased   High           Higher
  *PMEPA*     Increased          Increased   NT          NO             Higher
  *IL15Ra*    Increased          NT          Increased   NO             NO
  *KLF4*      Increased          NT          NO          Lower          Lower
  *CALD1*     Increased          NT          NT          High           Higher
  *TACSTD2*   Increased          NO          NT          Weak           Lower
  *NFAT5*     Increased          NT          NO          Weak           Lower
  *DDIT3*     Increased          NT          NT          Higher         Lower
  *Zc3h12c*   Increased          NT          NT          Lower          NO
  *MMP7*      Increased          NT          NT          NO             NO
  *CYR61*     Increased          NT          NT          High           Higher
  *CXCL2*     Increased          NO          NO          Lower          Lower
  *NEDD9*     Increased          Increased   NT          NO             NO
  *PDCD4*     Decreased          Decreased   NT          NO             NO
  *CXCR4*     Decreased          NT          NT          NO             Higher
  *FGFR4*     Decreased          NT          NO          Lower          Lower
  *NR0B2*     Decreased          NT          NT          Lower          Lower
  *CA9*       Decreased          NT          NT          NO             Lower
  *REG4*      Highly decreased   NT                      Lower          Higher

\(1\) Data are obtained from RT-PCR of COX-2 overexpresssing carcinoma cells (our data on HT-29, HCT116, or Caco2 or reported in the literature) compared to control cells. (2) Data are obtained from RT-PCR of PGE2 treated carcinoma cells (our data on HT-29, HCT116 and Caco2 or reported in the literature) compared to untreated control cells. (3) Data are obtained from RT-PCR of mPGES1 overexpresssing carcinoma cells (our data on HT-29, HCT116, and Caco2) compared to control cells. (4) Associated to significant worse prognosis in databases of patients with Colon adenocarcinoma <http://www.oncolnc.org/>; or (5) bioprofiling database (<http://www.bioprofiling.de/>). NT, Not tested or reported; NO, no effect; Higher means that high expression is associated with higher risk of death or metastasis; Lower means that high expression is associated with lower risk of death or metastasis.

Dual-Specificity MAPK Phosphatase 10 {#s4_1}
------------------------------------

Dual-specificity Mitogen Activated Protein Kinase (MAPK) phosphatase 10 (DUSP10), also named MPK5, was found altered by COX-2 overexpression in CRC cell lines in several data sets ([@B28]) included our own. DUSP10 is able to dephosphorylate p38 and c-Jun NH~2~-terminal kinase (JNK). Until recently, there were few reports regarding the putative role of DUSP10 in cancer. Most of those studies have found increased *DUSP10* mRNA in tumor tissue, thus suggesting a pro-tumorigenic role for this phosphatase ([@B59]). In CRC, the expression of certain DUSP10 polymorphisms are linked to an enhanced CRC risk ([@B29]).

We found that DUSP10 overexpression increased the growth of CRC cell lines and mouse xenografts, while the opposite phenotype was observed by DUSP10 silencing. Cancer progression is related to an uncontrolled cell division and DUSP10 overexpression produces the loss of cell-contact inhibition through the dephosphorylation of Yes-associated protein (YAP) at Ser397. This dephosphorylation retains YAP in the nucleus. In fact, we found that high amounts of DUSP10 and YAP1 are located in the nucleus of CRC cells ([@B58]). Additionally, the quantity of nuclear DUSP10 in CRC tumor biopsies is directly correlated with high tumor stage CRC and poor prognosis and survival in a large cohort of CRC patients, being also associated to high expression of nuclear YAP1. All these data point at DUSP10 as a downstream protein in COX-2 signaling and provide evidence of the role of DUSP10 in CRC progression *via* YAP1 regulation ([@B58]). Interestingly, an inhibitor of DUSP10 have been described ([@B47]), supporting its use in CRC.

Dual-Specificity MAPK Phosphatase 4 {#s4_2}
-----------------------------------

Another dual-specificity MAPK phosphatase, DUSP4/MKP-2, was also upregulated by COX-2. DUSP4 role in several cancers has been documented ([@B76]; [@B112]). An altered expression of DUSP4 is related to colon tumorigenesis. Thus, elevated DUSP4 expression is associated with microsatellite instability in CRC patients ([@B40]) being also associated with liver and lung metastases of CRC ([@B107]). Moreover, DUSP4 overexpression in CRC cell lines produced upregulation of MAPK targets, such as EGR1, FOS, and MYC, and downregulation of the mismatch repair gene MSH2, all these effects leading to an increase in cell proliferation ([@B40]). In contrast, it has been more recently reported that the decrease in the expression of DUSP4 in CRC cell lines activated ERKs, causing cell proliferation and invasiveness ([@B51]).

Interestingly, DUSP4 overexpression in CRC cell lines decreases their sensitivity to doxorubicin, a drug used to treat CRC ([@B62]). Moreover DUSP4 genetic inactivation increased the resistance to cetuximab, an epidermal growth factor receptor (EGFR)-blocking antibody, widely used and approved for treatment of metastatic CRC in cell lines and to another well‐known EGFR inhibitor, erlotinib ([@B92]). Interestingly, those effects are also related to COX-2 expression, since *DUSP4* was the highest induced gene in cetuximab-resistant CRC cells ([@B77]). All these data together point at DUSP4, enzyme regulated by COX-2, as a factor whose overexpression leads to CRC development and invasion, and which can be a promising therapeutic target. Moreover, DUSP4 specific inhibitors have been described ([@B91]) supporting its clinical testing in CRC at least in some drug resistant tumors.

Trophoblast Cell-Surface Antigen 2 {#s4_3}
----------------------------------

Trophoblast cell-surface antigen 2 (TROP2), also called Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), is a cell-surface glycoprotein expressed during embryonic and fetal development which is involved in cell proliferation, cell binding, motility, and metastasis ([@B80]). TROP2 overexpression can induce cancer growth and is associated with poor prognosis and drug resistance in cancer cells ([@B114]).

Our COX-2, but not mPGES1, overexpressing colon carcinoma cells present high levels of *TACSTD2*. Besides, high expression of *PTGS2* and *TACSTD2* genes have been found also associated in lung cancer metastasis ([@B21]). Previous studies in CRC patients, already showed the correlation between high expression of TROP2 and metastasis in CRC ([@B63]). The overexpression of TROP2 together with MMP7, another COX-2 induced gene (see below), is a predictor of worse prognosis and relapse in CRC ([@B32]). TROP2 expression enhances anchorage-independent growth in colon carcinoma cell lines ([@B135]) and its activation of TROP2 by Tumor Necrosis Factor (TNF)-alpha induces cell migration and invasion ([@B152]).

More importantly, an anti-TROP-2 antibody, sacituzumab govitecan, is a potential therapeutic drug for metastatic solid tumors ([@B121]). Since TROP2 is consistently induced by COX-2 overexpression, this makes it an alternative target to COX-2 blockade therapy in CRC.

Matrix Metalloproteinase- 7 {#s4_4}
---------------------------

Matrix metalloproteinases (MMPs) are proteolytic enzymes which degrade and remodel the extracellular matrix (ECM) in physiological processes, such as in cell migration, and have also been involved in metastasis ([@B153]). It has been reported that MMP7 is one of the most important MMPs in colorectal tumorigenesis, promoting angiogenesis, invasiveness, and tumor survival. Thus, MMP-7 may enhance CRC progression due to its proteolytic activity on several cell surface molecules as EGFR, Fas-L, etc. ([@B134]). MMP7 is abundantly synthesised by colon carcinoma cells ([@B153]). A study of CRC patients demonstrated an increase in COX-2 and MMP-7 expression when compared to normal tissue and colon polyps sample ([@B5]). High levels of MMP-7 together with PTEN down-regulation where detected in CRC and were related to tumor stage and progression ([@B8]). Moreover, COX-2 overexpression in carcinoma cells modulates the adhesive properties of MMPs ([@B130]; [@B131]). PGE~2~ can transactivate EGFR thereby inducing the proliferation of CRC cell lines and exerts its functions in part through molecules such as MMP-7 ([@B90]; [@B64]).

Krüppel-Like Factor 4 (KLF4) {#s4_5}
----------------------------

Krüppel-like factor 4 (KLF4) is a transcription factor that was firstly identified as a regulator of cell growth arrest being one of the most important factors in Cancer Stem Cells (CSC). It is expressed in differentiating cells and it is also known to have a role in apoptosis suppression ([@B37]). KLF4 mRNA is consistently and strongly induced in our COX-2 but not in mPGES1 overexpressing colon carcinoma cells and it was shown that COX-2 and KLF4 colocalized in carcinoma cells of CRC tumor samples ([@B113]). Moreover, in HT-29 colon cancer cells, the expression of KLF4 was induced by 15-Deoxy-Delta-12, 14 PGJ~2~, a downstream product of COX-2 signaling pathway ([@B18]).

It has been described that the levels of high KLF4 mRNA in normal tissues can be used as a prognostic indicator of survival in CRC patients ([@B72]), suggesting a regulatory role in CRC progression. In contrast, other reports have indicated a protumoral role of KLF4 in CRC. Thus, KLF4 was found in colon adenocarcinoma metastasis to the liver ([@B50]) and low KLF4 expression was found in poorly differentiated CRC tissues ([@B49]). A study performed in cancer stem cell (CSC)-enriched spheroid CRC cell lines revealed a role of KLF4 in the invasiveness, migration, resistance to treatment, and ability to generate tumors as well as in the induction CSCs markers in those cells ([@B73]).

Programmed Cell Death 4 (PDCD4) {#s4_6}
-------------------------------

The expression of programmed cell death 4 (PDCD4), a tumor suppressor protein that inhibits tumor development in many cancer types, is decreased in CRC and this downregulation in colon tumors has been related to worse prognosis ([@B75]). Several studies correlate PDCD4 overexpression with inhibition of cell proliferation and invasion in different tumor cancer cell types. In colon carcinoma cells, high levels of PDCD4 inhibited Akt signaling pathway, decreasing invasiveness ([@B136]). Moreover, a COX-2 inhibitor, NS-398, increases PDCD4 in HCA-7 cells, a colon cancer cell line ([@B150]), in agreement with our observation that is consistently downregulated by COX-2 overexpression in carcinoma cell lines. The overexpression of COX-2 in response to inflammation induces an increase in PGE~2~ production and PGE~2~ decreases PDCD4 protein levels through upregulation of miR-21 ([@B94]). MiR-21 role in cancer has been extensively studied and its upregulation may explain the intrinsic resistance of some cancers to chemotherapy ([@B95]), being miR-21 and PDCD4 inversely correlated in CRC ([@B15]; [@B48]). Thus increasing PDCD4 levels through pharmacological manipulation of miR-21 could represent a novel therapeutic strategy in the treatment of CRC, as an alternative to COX-2/PGE~2~ blockade in CRC.

Nuclear Factor of Activated T-Cells 5 {#s4_7}
-------------------------------------

Nuclear Factor of Activated T cells- 5 (NFAT5) is a transcription factor belonging to the NFAT family whose expression is upregulated by osmotic stress to difference with the other four members of this family ([@B99]). Dysregulation of NFAT signaling has been linked to tumor progression in several cancers ([@B99]). Interestingly, NFAT is a key transcription factor regulating COX-2 expression in CRC cell lines ([@B30]), suggesting the existence of a positive feedback loop between NFATs and COX-2. However, little is know on NFAT5 and CRC. We found NFAT5 is induced by COX-2 overexpression and it has been described that promotes metastasis through the induction of alpha(6)beta(4) integrin in human breast and colon tumors ([@B56]), and besides some associations between NAFT5 SNPs and CRC risk has been found ([@B117]). NFAT5 expression has also been associated to metastasis in other cancer types and to proliferation of lung adenocarcinoma cells ([@B41]).

COX-2 and the TGF-β Pathway {#s5}
===========================

Among the genes induced by COX2, we found in our arrays many genes of the TGF-β pathway, which we later confirmed by PCR ([**Table 2**](#T2){ref-type="table"}). Many of them are also induced by PGE~2~ treatment although in a much lower extent, suggesting that other COX2 derived products, as PGF~2α~, are also involved. Apart from those, some other genes induced by TGF-β were also induced by COX-2/PGs.

###### 

Induction of TGFβ pathway or p53 pathway genes by COX-2 overexpression or PGE~2~ treatment in HT-29 colon carcinoma cells.

  TGFβ pathway      COX-2        PGE~2~
  ----------------- ------------ ------------
  *TGFB1*           \+ 24 ± 4    \+ 3 ± 1
  *TGFBR1*          \+ 18 ± 3    \+ 3 ± 0.8
  *TGFBR2*          \+ 14 ± 3    \+ 2 ± 0.4
  *SMAD1*           \+ 20 ± 8    \+ 2 ± 0.6
  *SMAD3*           \+ 38 ± 3    \+ 3 ± 0.5
  *SMAD5*           \+ 35 ± 6    \+ 3 ± 0.5
  *SERPINE1*        \+ 7 ± 2     
  *EDN1*            \+ 25 ± 4    \+ 2 ± 0.2
  *ID1*                          \+ 2 ± 0.3
  *ENG*             \+ 36 ± 9    
  *CTGF*            \+ 2 ± 0.3   \+ 3 ± 0.5
  **p53 pathway**                
  *TP53*            \+ 10 ± 2    \+ 4 ± 1
  *MDM2*            \+ 28 ± 3    \+ 3 ± 1
  *CDKN1A*          \+ 7 ± 1     
  *TGFA*            \+ 46 ± 8    
  *GADD45*          \+ 20 ± 3    \+ 2 ± 0.5
  *PCNA*            \+ 8 ± 1     \+ 2 ± 0.3
  *BAX*             \+ 23 ± 4    \+ 2 ± 0.8
  *FASL*            \+ 25 ± 2    
  *TSP1*            \+ 34 ± 2    \+ 3 ± 0.7

Fold induction of indicated mRNA in HT-29 stably overexpressing COX-2 respect empty vector transfected cells or HT-29 treated with 1 µM PGE~2~ for 24 h. Results shown are the mean ± SD of 3 independent experiments.

One of them was Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1, also known as TMEPA1, transmembrane prostate androgen induced 1). PMEPA1 was first identified as being upregulated in renal cell carcinoma and was designated as solid tumor associated gene 1 (STAG1) ([@B101]). PMEPA1 is known to be induced by TGF-β and modulates TGF-β signaling by competing with SARA (SMAD Anchor for Receptor Activation) for R-SMAD binding to sequester R-SMAD phosphorylation and promoting lysosomal degradation of TGF-β receptor ([@B138]). PMEPA1, through a negative feedback loop, is described as the responsible to convert TGF-β from a tumor suppressor to a tumor promoter in breast cancer ([@B115]).

We have demonstrated that PMEPA1 is a COX-2, PGE~2~, PGF2α, and calcium (through Ionophore treatment) -induced gene in colon and ovary cancer cells ([@B60]). Furthermore, PMEPA1 is involved in differentiation of colon epithelial cells and high levels are also found in all phases of CRC development, including metastasis, in patients ([@B11]). Furthermore, its high expression in CRC is related to poor prognosis and postulated as a predictor of relapse risk ([@B145]; [@B151]). PMEPA1 is also overexpressed in intestinal tumors in Apc (Min) mice, which are prone to intestinal adenoma formation and is also dysregulated in human CRC adenomas ([@B103]).

A recent study using colon cancer cell lines revealed the role of PMEPA1 in cell migration and invasion through bone morphogenetic proteins (BMP) signaling pathway activation and phosphorylation of the transcription factors Smad1 and Smad5 ([@B151]), which also correlates with its described effect in ovarian cancer cells ([@B60]).

NEDD9 (Neural Precursor Cell Expressed, Developmentally Down-Regulated-9) or HEF1 (Human enhancer of filamentation 1) is a structural protein mainly found in epithelial cells, which is upregulated by TGF-β and expressed transiently during embryonic life in mice. Many functions have been attributed to NEDD9, among them, the transmission of growth control signals between focal adhesions. It has also been involved in melanoma tumorigenesis and, most notably, in metastasis ([@B88]; [@B129]; [@B71]).

NEDD9 was also identified as one of key genes in CRC, being upregulated in CRC tumors ([@B74]; [@B25]). Interestingly, two independent groups have shown that NEDD9 overexpression elicited the same effects as PGE~2~ treatment on cell proliferation, cell cycle progression, colony formation, migration, and xenograft tumor growth in colon carcinoma cell lines ([@B142]; [@B74]). Interestingly, those PGE~2~ effects were reversed by inhibition of NEDD9 expression, indicating that NEDD9/HEF-1 could be an important downstream mediator in the pro-tumoral activity of PGE~2~ in CRC. In this sense, it would be possible to develop inhibitors to disrupt NEDD9 interactions with oncogenic partners ([@B129]).

Cysteine Rich Angiogenic Inducer 61 (Cyr61/CNN1) is another TGF-β regulated gene ([@B44]). It is a member of the CNN family of extracellular matrix associated proteins, which induces cell division and differentiation, chemotaxis, angiogenesis, and adhesion. In CRC, high levels of this protein induce migration and increase invasiveness ([@B16]). Cyr61/CNN1 has been described as potential serum marker for CRC ([@B118]), whereas Cyr61 expression in the tumor tissue indicates poor prognosis in colon cancer patients being statistically associated with greater mortality ([@B57]). Altered activation of CYR61 gene enhancers occurs during CRC development, being CYR61 expression induced by FOXA1 and CBP in colon cancer cells pointing at both transcription factors as targets for CRC treatment ([@B143]). Interestingly, PGF2α through FP receptors can upregulate the expression of CYR61 mRNA ([@B144]). We also found a significant positive correlation of COX2, DUSP10 with CYR61 in colon carcinoma cell lines ([@B58]).

Caldesmon (CaD), a major actin-associated protein, is found in smooth muscle and non-muscle cells with contractile function. In normal cells, CaD regulates contraction through the binding to two of the components of the thin filaments, actin, and tropomyosin, in the presence of Ca^2+^ ([@B132]). CaD expression was reported in both adenomas and adenocarcinomas ([@B97]). There are two alternatively spliced isoforms of CaD, high (h-CaD) and low (l-CaD), which differ in their molecular weight. H-CaD levels are lower in the late stages of colorectal adenocarcinoma while the low-molecular weight variant expression varies during tumor development and it is related to metastasis ([@B68]; [@B67]). CaD is absent in the stroma in CRC but present in smooth muscle, thus it is a marker for desmoplasia and tumor invasiveness of the large intestine's muscularis propria ([@B105]). It has been also described that CaD mRNA levels are higher in colon carcinoma cell lines than in non-transformed normal colon epithelial cells ([@B85]).

However, little is known about the role of the protein in the carcinogenic process. CaD is an important regulator of podosome formation which is involved in the degradation of the extracellular matrix (ECM), promoting in this way cell invasion, that is required for metastasis ([@B148]). L-CaD overexpression promotes expression of the regulatory p21 and c-PARP and suppresses NF-κB and phosphorylated mTOR expression, whereas its suppression increases sensitivity to chemo- and radiotherapy in colon carcinoma lines ([@B67]). TGF-β1 regulates the expression and phosphorylation of CaD in epithelial cells modulating epithelial-mesenchymal (EMT) transition ([@B84]).

COX-2 and the p53 Pathway {#s6}
=========================

The role of p53 in cancer in general and CRC in particular is well known \[reviewed in ([@B26]; [@B139])\]. Mutations in the tumor suppressor gene TP53, which encodes the protein p53, are frequently found in human cancers. Mutations in K-ras, adenomatous polyposis coli (APC), and p53 induce the transition from healthy colonic epithelia to CRC ([@B27]).

Among the genes induced by COX-2, we found in our arrays many genes of the p53 pathway, as it was found for the TGF pathway, that were also later confirmed by PCR ([**Table 2**](#T2){ref-type="table"}). Among those are TGFα, as well as others involved in cell cycle, apoptosis, DNA repair, and angiogenesis that my explain some of the diverse pro-tumoral activities of COX-2 in CRC. Again some of them were also induced by exogenous addition of PGE~2~ but in lesser extent, further suggesting that other prostaglandins, likely PGF~2α~, may be involved.

In addition, there is a well-known crosstalk between p53 and COX-2, in which COX-2 decreases p53 transcription, and p53 also regulates COX-2 expression ([@B26]). Furthermore, many COX-2 inducers, such as hypoxia, cytokines, oncogene activation, carcinogens, and inflammation, can also activate p53. The role of p53 in the regulation of COX-2 expression and activity has been extensively described. Thus, it has been reported the increase in COX-2 transcript in human tumor cells expressing p53 ([@B43]; [@B26]). COX-2 upregulation by p53 has been attributed to an increase on the binding of NF-κB to COX-2 promoter in response to p53 overexpression ([@B6]). Conversely, COX-2 avoids the transcriptional activity of p53 on target genes ([@B26]). COX-2 is not only regulating p53 function but also its subcellular localization, as it was demonstrated in human colon cell lines treated with celecoxib, a COX-2 inhibitor, in which p53 nuclear location was promoted ([@B125]). Interestingly, joint nuclear expression of COX-2 and p53 was significantly associated with adenoma recurrence in CRC ([@B9]).

Nonetheless there is less reported evidence of COX-2 effects on the p53 pathway. Interestingly our analyses have defined many p53 related genes that are modulated by COX-2 overexpression in colon carcinoma cells. Many of them were not described before as modulated by COX-2 and can provide clues in new therapeutic approaches.

Conclusion {#s7}
==========

COX-2 has been identified through clinical trials, epidemiological meta-analyses, and preclinical models and as a key molecule in the development of CRC. However, the use of specific COX-2 inhibitors in the clinic has been hampered by their side effects. The identification of genes regulated by COX-2 activity has allowed us to identify some genes that have been already implicated in several aspects of CRC development and therapy. The relationships among those genes and with the PG pathways are summarized in [**Figure 2**](#f2){ref-type="fig"}.

![Connection within the different genes upregulated by COX2 and likely involved in colorectal cancer (CRC) tumors. The continuous arrows are of direct interaction/activation while the discontinuous ones are indirect activation in which intermediaries participate.](fphar-11-00533-g002){#f2}

Of all molecules described here, some of them are more amenable to drug discovery. Besides some molecules had already specific inhibitors developed, as the phosphatases DUSP10 and DUSP4, as well as monoclonal antibodies to TROP2. This, together with the clinical evidence available in CRC, pointed out to these 3 molecules as the most suitable to be considered as putative drug targets and to engage in clinical trials especially in drug resistant settings or advanced CRC stages most likely in combination therapy. Also the interaction of the TGF-β and COX2 pathway deserve further clinical exploration. In summary, drugs targeting the COX-2 downstream molecules described will likely lack the unwanted side effects of COX-2 pharmacological inhibitors, providing alternative approaches in colon cancer.
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